ICU Medical Inc. research snapshot
ICUI AI stock analysis currently reads ICU Medical as a specialized medical technology company serving the IV therapy, infusion pump, oncology drug delivery, and critical care monitoring markets. The analysis is not a guaranteed price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $154.42, market capitalization was about $3.86 billion, and the main question was whether the recently improved Q1 2026 earnings, the Otsuka IV solutions partnership, and the ongoing $500 million Texas expansion can sustain the turnaround momentum and justify the high-80s TTM earnings multiple. This is informational research and not investment advice.
Current price
$154.42
Market cap
$3.86 billion
AI score
60 / 100
Rating
Niche medical technology operator with improving margins and a demanding valuation
Trend status
Short-term uptrend from 52-week low near $107 into the $154 area, testing resistance near recent highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ICU Medical provides IV therapy, infusion pumps, oncology drug delivery systems, and critical care monitoring products that hospitals depend on daily. Recurring consumable revenue provides stability, but growth has been modest. | Medium |
| Moat | Regulatory approvals, hospital relationships, manufacturing scale, and switching costs from integrated infusion systems create a moderate moat. Competitive pressure from B. Braun, Becton Dickinson, Baxter, and Fresenius limits pricing power. | Medium |
| Management | CEO Vivek Jain has been leading since 2020, focusing on margin improvement, debt reduction, and the Otsuka IV solutions JV. Early results are visible in Q1 2026 profitability, but a longer track record is still being built. | Medium-low |
| Financial trend | TTM revenue was about $2.16 billion with net income of roughly $46 million, showing mixed profitability across quarters. Q1 2026 net income of $30.13 million and EPS of $1.97 beat analyst estimates. | Medium-high |
| Valuation | The stock traded near 83x TTM earnings and roughly 77x TTM free cash flow at the cutoff, reflecting the market pricing in a significant earnings recovery. There is limited margin of safety at these multiples. | Medium |
| Technical trend | ICUI traded well above its 52-week low of $107 and moved toward the 52-week high of $162, with improving volume and momentum. The stock was near the upper end of its recent range. | Medium |
| Risk level | Key risks include high debt from the Hospira acquisition, customer concentration, competition from larger medtech players, regulatory compliance costs, and the risk that margin improvement stalls. | Medium |
| AI confidence | Medium-high confidence for the business map, Q1 2026 filings, market cap math, and major risk categories. Lower confidence for the durability of margin expansion and revenue growth trajectory. | Medium-high data confidence |
| Investment certainty | Medium-low certainty. ICU Medical has an essential product portfolio and is showing operational improvement, but the stock price already embeds high expectations for continued earnings recovery. | Medium-low |
ICUI AI stock forecast
The ICUI AI stock forecast uses scenario ranges around the $154.42 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires continued margin improvement, strong IV solution demand through the Otsuka partnership, and successful debt reduction. The base case assumes modest revenue growth with gradually improving margins. The bearish case assumes competitive pressure or operational setbacks that slow the turnaround.
$185 to $220
More likely if ICU Medical sustains double-digit EPS growth, the Otsuka IV solutions partnership drives revenue acceleration, the Texas expansion adds capacity without margin dilution, and debt reduction allows multiple expansion toward 25x forward earnings.
$135 to $165
More likely if revenue grows at a low-to-mid single digit pace, margins stabilize near Q1 2026 levels, and the stock trades in a range reflecting steady but unexciting improvement.
$90 to $120
More likely if competitive pressure from larger medtech players intensifies, the Hospira integration and Texas expansion face cost overruns, or hospital capital spending slows, pressuring margins and revenue.
ICUI AI technical analysis
ICUI AI technical analysis starts from the $154.42 July 10 close used for this July 12 static page. Public technical sources showed the stock well above its 52-week low and approaching the 52-week high area. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $154.42 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $140 to $145 | The area around the 20-day and 50-day moving averages. A hold above this zone supports the recent uptrend. |
| Secondary support | $120 to $125 | A deeper support zone that would come into play if the 50-day area is broken. Corresponds to prior consolidation levels. |
| Near resistance | $158 to $162 | The 52-week high area. A breakout above this zone with volume would signal a continuation of the uptrend. |
| 52-week range | $107.02 to $162.18 | The full 52-week range. The stock was trading in the upper third of this range at the cutoff. |
| Momentum | RSI neutral to bullish, improving | Momentum indicators have been improving as the stock recovered from the 52-week low. RSI was in neutral-to-bullish territory. |
| Volume | About 204,000 shares (Jul 10) | Below the average volume of about 314,000. Breakout attempts or breakdowns should ideally be confirmed by above-average volume. |
| Volatility | Beta 0.76 | Low-to-moderate beta relative to the market. Position sizing should account for normal daily movement around the cutoff price. |
| Invalidation | Close below $140, then $120 | A close below the $140 area would weaken the near-term technical setup. A break below $120 would challenge the broader recovery trend. |
ICUI AI trading strategy
The ICUI AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for ICUI to hold above the $140 support area and break above the $158 to $162 52-week high zone on expanding volume before treating momentum as confirmed.
A failed breakout or daily close below the $140 area should reduce confidence in the continuation setup.
If ICUI pulls back toward the $140 to $145 support zone without a fundamental thesis break, compare price stabilization with upcoming earnings momentum, Otsuka partnership developments, and margin trajectory.
Do not average down solely because the stock is off recent highs. Define maximum loss and review the quarterly earnings trajectory and debt profile first.
Track Q2 2026 and full-year 2026 revenue growth, gross margin trends, debt-to-EBITDA ratio, Otsuka JV revenue contribution, and free cash flow generation.
Lower the rating if revenue growth slows below expectations while the stock continues to trade at a premium multiple, or if debt reduction stalls.
Investment research summary
ICU Medical sells essential IV therapy products, infusion pumps, and oncology drug delivery systems that hospitals and clinics use daily to deliver fluids, medications, and blood products to patients.
The moat comes from FDA-cleared product designs, hospital procurement relationships, installed infusion pump fleets that create switching costs, and manufacturing know-how for sterile IV solutions and medical devices.
The thesis can fail if large competitors use scale to undercut pricing, the Otsuka JV does not deliver expected synergies, the Texas expansion overshoots demand, or the debt burden from the Hospira acquisition constrains strategic flexibility.
CEO Vivek Jain has refocused the company on margin improvement, debt reduction, and the Otsuka IV solutions partnership. The Q1 2026 earnings beat is encouraging, but building a sustained track record takes time.
Demand for IV therapy, infusion systems, and safe drug delivery is structurally supported by aging populations and increasing chronic disease prevalence. The trend is favorable but competitive intensity remains high.
At roughly 83x TTM earnings and 77x TTM free cash flow, the stock price embeds high expectations for margin improvement and earnings growth. A margin of safety would require either lower entry price or stronger evidence of sustained operating leverage.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ICUI price | $154.42 close on July 10, 2026 | Google Finance and Yahoo Finance | July 12, 2026 |
| Market capitalization | $3.86 billion, verified as $154.42 x 24,990,000 shares | financial_rigor.py market cap verification and Google Finance | July 12, 2026 |
| Q1 2026 revenue | $530.22 million | Google Finance income statement data | July 12, 2026 |
| Q1 2026 net income | $30.13 million | Google Finance income statement data | July 12, 2026 |
| Q1 2026 EPS | $1.97, beat analyst estimate of $1.76 | Google Finance earnings data and analyst reports | July 12, 2026 |
| TTM revenue | About $2.16 billion | Sum of last four quarterly revenue figures from Google Finance | July 12, 2026 |
| TTM net income | About $46 million | Sum of last four quarterly net income figures from Google Finance | July 12, 2026 |
| Shares outstanding | Approximately 24.99 million | Google Finance | July 12, 2026 |
| Valuation math | 83.47x TTM PE, 77.21x TTM P/FCF, 1.20% earnings yield from financial_rigor.py | financial_rigor.py valuation verification | July 12, 2026 |
| 52-week range | $107.02 to $162.18 | Google Finance | July 12, 2026 |
This ICUI AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
